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ABSTRACT
Tripartite motif-containing protein 5 (TRIM5) restricts human immunodeficiency virus type 1 (HIV-1) in a species-specific
manner by uncoating viral particles while activating early innate responses. Although the contribution of TRIM5 proteins to
cellular immunity has not yet been studied, their interactions with the incoming viral capsid and the cellular proteasome led us
to hypothesize a role for them. Here, we investigate whether the expression of two nonhuman TRIM5 orthologs, rhesus TRIM5
(RhT5) and TRIM-cyclophilin A (TCyp), both of which are potent restrictors of HIV-1, could enhance immune recognition of
infected cells by CD8 T cells. We illustrate how TRIM5 restriction improves CD8 T-cell-mediated HIV-1 inhibition. More-
over, when TRIM5 activity was blocked by the nonimmunosuppressive analog of cyclosporine (CsA), sarcosine-3(4-methylben-
zoate)–CsA (SmBz-CsA), we found a significant reduction in CD107a/MIP-1 expression in HIV-1-specific CD8 T cells. This
finding underscores the direct link between TRIM5 restriction and activation of CD8 T-cell responses. Interestingly, cells ex-
pressing RhT5 induced stronger CD8 T-cell responses through the specific recognition of the HIV-1 capsid by the immune sys-
tem. The underlying mechanism of this process may involve TRIM5-specific capsid recruitment to cellular proteasomes and in-
crease peptide availability for loading and presentation of HLA class I antigens. In summary, we identified a novel function for
nonhuman TRIM5 variants in cellular immunity. We hypothesize that TRIM5 can couple innate viral sensing and CD8 T-cell
activation to increase species barriers against retrovirus infection.
IMPORTANCE
New therapeutics to tackle HIV-1 infection should aim to combine rapid innate viral sensing and cellular immune recognition.
Such strategies could prevent seeding of the viral reservoir and the immune damage that occurs during acute infection. The non-
human TRIM5 variants, rhesus TRIM5 (RhT5) and TRIM-cyclophilin A (TCyp), are attractive candidates owing to their po-
tency in sensing HIV-1 and blocking its activity. Here, we show that expression of RhT5 and TCyp in HIV-1-infected cells im-
proves CD8 T-cell-mediated inhibition through the direct activation of HIV-1-specific CD8 T-cell responses. We found that
the potency in CD8 activation was stronger for RhT5 variants and capsid-specific CD8 T cells in a mechanism that relies on
TRIM5-dependent particle recruitment to cellular proteasomes. This novel mechanism couples innate viral sensing with cellular
immunity in a single protein and could be exploited to develop innovative therapeutics for control of HIV-1 infection.
Early immunity against viral infections is critical in controllingdisease course (1). In the case of HIV-1, early immunity is
thought to be too late and too weak to control the irreversible
damage established during acute infection through viral cyto-
pathic effects (2). A combination of potent early innate and adap-
tive immune responses is required for effective virological control
and sustained protection against viral infections (3).
Innate antiviral proteins, also called restriction factors, are the
first intracellular barriers against HIV-1 infection. Restriction fac-
tors mediate rapid viral sensing, thus enabling HIV-1 suppression
within hours and before adaptive immunity can be engaged. Tri-
partite motif-containing protein 5 (TRIM5) exhibits one of the
strongest signatures of evolutionary selection pressure in mam-
malian genomes and mediates cross-species recognition of retro-
viruses (4, 5). TRIM5 variants from Old World monkeys, such as
rhesusmacaques, restrict a broad spectrumof human retroviruses
(HIV-1 and HIV-2) and animal retroviruses (equine infectious
anemia virus [EIAV] and N-tropic murine leukemia virus [N-
MLV]).Meanwhile, NewWorldmonkeys do not generally restrict
HIV-1 (6). An exception is found in New World owl monkeys,
where TRIM5 has gained a cyclophilin A-derived virus-binding
domain and restricts HIV-1 very efficiently.
Although the precise molecular interactions between HIV-1
and TRIM5 are not fully understood, TRIM5 has two comple-
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mentary antiviral functions that both rely on the recognition of
the HIV-1 capsid lattice. The first is its function as a restriction
factor, through direct binding to the incoming retrovirus and dis-
ruption of the capsid by a proteasome-dependent TRIM5 mech-
anism (7–9). The second is its function as a pattern recognition
receptor, which it carries out by promoting the secretion of type I
interferons (IFNs) (10). Thus, innate cellular recognition by
TRIM5 constitutes a host frontline defense against initial viral
spread.
Together with innate viral sensing, cellular immune responses,
and particularly HIV-1-specific CD8 T-cell responses, are cru-
cial for the control of both acute and chronic viral infections. The
key role of adaptive immunity in control of HIV-1 infection is
seen clearly in the associations between the expression of specific
HLA class I molecules and HIV-1 disease outcome (11–13), the
breadth of Gag-specific CD8 T-cell responses and virological
control (14, 15), and the emergence of immune escape variants
against CD8 T-cell responses (16, 17). Moreover, recent studies
have demonstrated how some restriction factors (APOBEC3G
and SAMHD1) canmodify cellular immunogenicity and recogni-
tion of HIV-1-infected cells by CD8 T cells (18, 19), thus sug-
gesting a complex interdependency between intracellular innate
viral sensing and adaptive immunity.
In the case of TRIM5, the interaction with the adaptive im-
mune system remains unknown. However, knowledge of such an
interaction might be crucial for the development of novel thera-
peutic strategies, which would seek to combine potent intracellu-
lar viral sensing with antiviral CD8 T-cell responses to generate
protective immunity against HIV-1. Here, we describe a series of
experiments to underscore the role of TRIM5 in CD8 T-cell
antiviral activity.We studiedTRIM5 variants that potently restrict
HIV-1 infection (rhesus TRIM5 [RhT5] and New World owl
monkey TRIM-cyclophilin A [TCyp]) and developed an in vitro
model of RhT5 and TCyp expression in HIV-1-susceptible cell
lines. Using this model, we evaluated HIV-1 restriction and
changes in the antigenicity of infected cells for antiviral CD8
T-cell recognition. Furthermore, we tested the specific contribu-
tion of TRIM5 variants to the activation of HIV-1-specific CD8
T cells and evaluatedwhether the resulting interactions depend on
CD8 T-cell protein specificity. Our data demonstrate the direct
contribution of TRIM5 variants to induction of HIV-1-specific
CD8T-cell responses by coupling innate and adaptive immunity
in HIV-1-infected cells.
MATERIALS AND METHODS
Generation of stableU937 cell lines expressing nonhumanTRIM5 vari-
ants. In order to assess epitope presentation in the context of nonhuman
TRIM5 expression, we used a U937 cell line that was transfected and
selected for the expression of HLA-B*2705 (20). The U937 HLA-B*2705
cells were transduced with lentiviral vectors that confer puromycin resis-
tance and encode either of the two TRIM5 isoforms, namely, the rhesus
TRIM5 (RhT5) or the owl monkey TRIM cyclophilin A (TCyp) fusion
gene. Control cells were transduced with the empty lentiviral vector.
Transduced cell lines were selected in the presence of 1.25g/ml of puro-
mycin (Sigma) and maintained in medium containing RPMI 1640 me-
dium (Invitrogen), 10% fetal calf serum, penicillin (100 U/ml), strepto-
mycin (100 g/ml), G418 (0.5 mg/ml), and puromycin (1.25 g/ml)
(Sigma). We quantified TRIM5 mRNA in transduced cells. Briefly, RNA
was extracted from 5 106 U937 cells expressing an empty vector (EV),
RhT5, or TCyp (RNeasy RNA extraction kit; QIAgen, United Kingdom).
The RNA extracted was treated with DNase (Turbo DNA-free kit;
Thermo Fisher Scientific) to remove residual DNA. cDNA from 1 g of
DNase-treated RNA was synthesized with SuperScript III reverse trans-
criptase (ThermoFisher Scientific). cDNAwas diluted 1:5 in nuclease-free
H2O, and 2l was used for real-time PCRquantificationwith SYBR green
PCR master mix (Applied Biosystems) in a 7500 Fast Real-Time PCR
system (Applied Biosystems) and in three technical triplicates with the
following primers: RhT5 forward (FWD), 5=-CGCTACTGGGTTGATGT
GACAC-3=, and RhT5 reverse (REV), 5=-CCCTGGTGCCTGATACATT
ATCTG-3= (21); TCyp FWD, 5=-CAGAAGTCCAACGCTACTGGG-3=,
and TCyp REV, 5=-CTTGCCACCAGTGCCATTATGG-3= (22). RhT5-
and TCyp-coding plasmids were used as standards for quantification of
mRNA in each gene.
Virus and CD8 T-cell lines. Virus HIV-1GFP was produced by
cotransfecting the HIV-1 packaging plasmid pCMVR8.2, the green fluo-
rescent protein (GFP)-encoding vector genome pCSGW, and the vesicu-
lar stomatitis virus (VSV)Gprotein-encoding plasmid pMDG in a ratio of
4:1:1 into 293T cells using FuGENE. Viruses were harvested at 48 h post-
transfection. Viral stocks were purified through a 20% sucrose cushion,
concentrated by ultracentrifugation at 4°C and 24,000 rpm for 90 min,
and stored at80°C. The 50% tissue culture infective dose (TCID50) for
HIV-1GFP particles was determined in EV-expressing U937 cells by limit-
ing dilution for 48 h postinfection using the Reed and Muench method.
TheNL43-VprGFP virus was produced by calcium phosphate cotransfec-
tion of a plasmid expressing NL4-3 and one expressing Vpr-GFP at a 1:1
ratio (23) into 293T cells. Viruses were harvested at 48 h posttransfection,
purified, and concentrated as previously mentioned.
The HLA-B*2705-restricted CD8 T-cell lines specific for the HIV-1
KK10 epitope in Gag and the KY9 epitope in Pol and the HLA-B*5701-
restricted CD8 T-cell lines specific for the HIV-1 KF11 epitope were
obtained as previously described (24). Cells were cultured inH10medium
containing RPMI 1640medium (Invitrogen) supplemented with 10%AB
human serum (Invitrogen), 10% natural T-cell grow factor (TCGF) (Hel-
veticaHealthcare), 100U/ml of penicillin, and 100g/ml of streptomycin
(Invitrogen). After 3 days in culture, cells were fed withH10medium, and
once a week the cultures were stimulated with a mixture of 1:1 irradiated
peptide-pulsed (10 g/ml) autologous B-cell lines and peripheral blood
mononuclear cells (PBMCs) from three HIV-1-seronegative donors.
HIV-1 restriction experiments. U937 cells expressing RhT5, TCyp,
and the control (EV) were infected with a VSV-pseudotyped HIV-1GFP at
a dose equivalent to a nominal multiplicity of infection (MOI) of 0.2 on
EV-expressing cells for 2 h at 37°C. In some experiments, cyclosporine
(CsA; 5 M) or sarcosine-3(4-methylbenzoate)–CsA (SmBz-CsA; 5 M)
was added to the culture at the time of infection. GFP was measured by
flow cytometry at 22 h postinfection.
CD8 T-cell inhibition and killing experiments. The EV-, RhT5-,
and TCyp-expressing cells were infected withHIV-1GFP in the presence of
5 M CsA at a dose equivalent to an MOI of 0.2 on EV-expressing cells.
After 2 h of infection, cells were cultured in the absence or the presence of
HLA class I-matched CD8 T cells at an effector-to-target ratio (E/T) of
1:2 (24). Moreover, to control for unspecific CD8 T-cell activation,
HIV-1-infected cells were cultured in the presence of HLA class I-mis-
matched (MM)CD8T cells. Approximately one-third of the culture was
collected at 3, 6, and 22 h postinfection, and Live/Dead staining and stain-
ing for expression of CD4, CD8, andGFP in infected cells were carried out
for all samples. HIV-1 CD8 T-cell inhibition was calculated as follows:
100 [(% GFP cells in CD4 coculture with CD8 cells/% GFP cells
in CD4 cells in the absence of CD8)  100] (where GFP is GFP-
positive). The number of live CD4 cells was calculated as follows: [% live
CD4 cells in coculture with CD8 cells/% live CD4 cells in the absence
of CD8 cells] 100. In addition, to verify the functionality of the CD8
T cells used in the experiments, we measured the frequency of MIP-1/
CD107a-positive cells in response to CD8 T-cell coculture with HLA
class I-matched B-cell lines loaded with cognate peptide.
CD8T-cell functionality.HLA class I-matched B-cell lines and EV-,
RhT5-, and TCyp-expressing cells were loaded with cognate peptide (2
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g/ml) for 1 h in the presence of cyclosporine (5M), SmBz-CsA (5M),
or no drugs. After that, CD8 T cells were added to the culture in an E/T
ratio of 2:1 in the presence of CD107a and incubated for 3 h in the pres-
ence of brefeldin A (10 g/ml) and GolgiStop. CD8 T-cell functionality
was examined by measuring the proportion of CD107a/MIP-1-positive
cells by intracellular cytokine staining.
CD8 T-cell activation experiments. (i) Flow cytometry.RhT5- and
TCyp-expressing cells were infectedwithHIV-1GFP at anMOIof 0.2 in the
presence of aztreonam (AZT; 5 M), CsA (5 M), or SmBz-CsA (5 M)
or without drugs. After 2 h of infection, Gag or Pol HLA class I-matched
CD8 T cells were added to the culture in the presence of CD107a at an
E/T ratio of 1:2. In addition, HLA class I-mismatched CD8 T cells were
included to control for nonspecific activation. Samples were collected at
22 h postinfection and stained with Live/Dead stain and for CD4, and
CD8 surface markers and CD107a and MIP-1 intracellular expression.
To compare experiments, the frequency of CD8 T-cell activation was
calculated as relative activation in relation to the maximum level of
CD107a/MIP-1 expression achieved in the experiment for any of the
conditions tested as 100%.
(ii) IFN- ELISPOT. RhT5- and TCyp-expressing cells were infected
with HIV-1GFP at a dose equivalent to an MOI of 0.5 on EV-expressing
cells for 24 h. Infected cells were cocultured with HIV-1 Gag- or Pol-
specific CD8 T cells at various E/T ratios (1:16, 1:8, 1:4, and 1:2) and
incubated overnight. For positive controls, RhT5- and TCyp-expressing
cells were loadedwith cognate peptide and coculturedwithHIV-1Gag- or
Pol-specific CD8 T cells. For negative controls, RhT5- and TCyp-ex-
pressing target cells alone were cocultured with HIV-1 Gag- or Pol-spe-
cific CD8 T cells. IFN- production was measured using enzyme-linked
immunosorbent spot (ELISPOT) assays, and the background production
by negative controls was subtracted from all samples.
In order to test additional HIV-1-specific CD8 T cells, H9-B*5701
cells were transiently transduced with the EV (empty vector)-expressing
and rhesus TRIM5 (RhT5)-expressing lentiviral vectors that confer pu-
romycin resistance. After 72 h of lentiviral transduction and 48 h in pu-
romycin (1.25 g/ml) (Sigma) cells were infected with HIV-1GFP at an
MOI of 0.5 for 24 h. Infected cells were cocultured with HLA-class I-
matched HIV-1 Gag-specific CD8 T cells at an E/T ratio of 1: 2 over-
night. H9 EV- and RhT5-expressing cells were loaded with cognate pep-
tide and cocultured with HIV-1 Gag-specific CD8 T cells for positive
controls. We performed a similar experiment in U937 HLA-B*2705 cells
in cocultures withHLA-class I-matchedHIV-1 Gag-specific CD8T cells
as the control.
Surface and intracellular antibody staining. Depending on the ex-
periments, cell populations were labeled with combinations of the follow-
ing antibodies: Live/Dead stain (APC-CY7; Invitrogen), CD4 (clone SK3;
BD), CD8 (clone RPA-T8; BD), p24 (clone KC57-RD1; Coulter Clone),
MIP-1 (clone 24006; R&D Systems), and CD107a (clone H4A3; BD).
The intracellular staining assay was performed as described previously
(25), with some modifications. Briefly, CD107a was added to the culture
with CD8 T cells and incubated for an additional 3 h in the presence of
brefeldin A (10 g/ml) and GolgiStop. Cells were then stained first with
Live/Dead stain and for surface markers of CD4 and CD8 and fixed with
1% formaldehyde overnight. The following day, the cells were permeab-
ilized with buffer containing saponin and stained for p24 and/orMIP-1.
All samples were fixed for 2 h with 1% formaldehyde before being ac-
quired on an LSRII flow cytometer. Data were analyzed with FlowJoV
(Tree Star Inc.).
Immunofluorescent staining. U937 cells expressing EV, RhT5, and
TCyp or HeLa cells expressing EV, RhT5, or TCyp were infected with
NL43-VprGFP for 2 h at 37°C. In addition, EV- andTCyp-expressing cells
in the absence or presence of 5 M SmBz-CsA were infected with NL43-
VprGFP for 2 h at 37°C. For the different experiments, following infection
cells were fixed, stained for the 19S proteasome subunit (BML-PW8825;
Enzo Life Sciences), and revealedwith the secondary antibodyAlexa Fluor
555 (A 21424; Invitrogen). Cells were cytospun onto coverslips and
mounted with 4=,6=-diamidino-2-phenylindole (DAPI) mounting me-
dium (Invitrogen). Images were collected as described by Izquierdo-Use-
ros et al. (26) with anUltraview ERS spinning disk system (Perkin-Elmer)
mounted on aZeiss Axiovert 200M invertedmicroscope. To obtain three-
dimensional (3-D) reconstructions and count virus/proteasome contacts,
confocal Z stacks were processed with Volocity software (Perkin-Elmer)
using the isosurface module.
Statistical analyses. Statistical tests were performed using GraphPad
Prism (GraphPad Software, Inc.). P values were calculated using aMann-
Whitney test, Wilcoxon signed-rank test, or two-way analysis of variance
(ANOVA). Spearman correlation coefficients were calculated between
p24 and GFP expression. P values of 	0.05 were considered statistically
significant.
RESULTS
Nonhuman TRIM5 variants improve inhibition of HIV-1-in-
fected cells by CD8 T cells. In order to investigate the role of
TRIM5 in retroviral restriction and CD8 T-cell antiviral activity,
we expressed two nonhuman TRIM5 orthologs (RhT5 and TCyp)
that potently restrict HIV-1 using lentiviral vectors in U937 cells.
The same lentiviral EVwas used as a control (Fig. 1A). Since U397
cells are susceptible to HIV-1 infection and express HLA-B*2705,
we can rapidly evaluate HIV-1 infectivity and CD8 T-cell inhi-
bition (20, 24). In addition, theVSV-pseudotypedHIV-1 particles
that express GFP upon viral integration (HIV-1GFP) used here
enabled us to easily measure TRIM5 antiviral activity (Fig. 1A).
TRIM5mRNA expression levels were similar between transduced
cell lines (Fig. 1B). As shown in Fig. 1C, RhT5- and TCyp-express-
ing cells restricted HIV-1 significantly more than EV-expressing
control cells (RhT5, 6.98%; TCyp, 19.17%; EV, 53.8%; mean val-
ues, P	 0.0001 for all data set comparisons) (Fig. 1C). Moreover,
the restriction phenotype was consistent at different MOIs (0.2
and 0.5) (data not shown) and specific to TRIM5 expression, as
observed by blocking TCyp activity with CsA, which binds to the
cyclophilin domain in TCyp and fully rescues HIV-1 infectivity
(Fig. 1C).
We next assessed whether TRIM5 expression in HIV-1-in-
fected cells affects suppression mediated by HIV-1-specific CD8
T cells. We infected EV-, RhT5-, and TCyp-expressing cells with
HIV-1GFP and cocultured them with HLA class I-matched HIV-1
Gag-specificCD8T cells. To control for nonspecificCD8T-cell
activation, we cocultured infected cells with HLA class I-mis-
matched (MM) CD8 T cells under similar conditions. HIV-1
CD8 T cell-mediated inhibition was assessed by differences in
GFP expression levels over time (3, 6, and 22 h postinfection) in
the presence or absence of CD8 T cells (Fig. 1D and E). We
consistently demonstrated significant increases inHIV-1-specific,
CD8T-cell-mediated inhibition ofHIV-1-infected cells express-
ing TCyp (77.2%) and RhT5 (66.8%), compared with control
EV-expressing cells (44.5%) (TCyp versus EV, P 
 0.003; RhT5
versus EV, P 
 0.003). The strongest effect was observed with
TCyp (Fig. 1F) (TCyp versus RhT5, P 
 0.003). Critically, this
effect reverted to background levels when TCyp activity was
blocked using CsA.
Moreover, differences in HIV-1-specific CD8 T-cell inhibi-
tion levels translate as a reduction of live RhT5- and TCyp-ex-
pressing cells infected with HIV-1 in the presence of CD8 cells
(TCyp versus EV, P 
 0.0007; RhT5 versus EV, P 
 0.013) (Fig.
1G). TCyp had the strongest effect on CD8 T-cell inhibition but
not on total killing of infected cells (Fig. 1F and G). This discrep-
ancy could be due to the fact that the weaker restriction mediated
Jimenez-Moyano et al.
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FIG 1 HIV-1-specific CD8 T-cell inhibition in HIV-1-infected cells expressing TRIM5. (A) U937 cells were transduced with a lentiviral empty vector (EV) or
vectors coding for rhesus TRIM5 (RhT5) or owlmonkey TRIM-cyclophilin A (TCyp) and conferring resistance to puromycin. Stable transduced cell lines with
EV, RhT5, and TCyp expression were infected with vesicular stomatitis virus (VSV)-pseudotyped HIV-1 GFP (HIV-1GFP), and retroviral restriction was
quantified according to the frequency of GFP cells by flow cytometry. (B) mRNA copy numbers of TRIM5 in U937 cells expressing EV, RhT5, and TCyp. The
graph shows the mean standard error of the mean of three technical replicates. (C) Percentage of GFP cells in cells expressing EV, RhT5, TCyp, and TCyp in
the presence of 5MCsA after infection with HIV-1GFP. The graph shows the mean standard error of the mean of six independent experiments performed in
triplicate. TheP valueswere calculated using aMann-Whitney test. (D) Zebra plots representative ofHIV-1-specificCD8T-cell-mediated inhibition in infected
cells expressing EV, RhT5, TCyp, and TCyp plus CsA. The percentage of GFP cells at 22 h postinfection was determined in uninfected HIV-1-infected cells and
inHIV-1-infected cells in coculture withHLA class I-matchedGag-specific CD8T cells. (E) Kinetics ofHIV-1 infection in the absence (empty dots) or presence
(colored dots) of HLA class I-matched CD8 T cells in cells expressing EV, RhT5, TCyp, and TCyp plus CsA, as indicated. EVMM, cells expressing EV in the
presence of HLA class I-mismatched CD8 T cells. (F) HIV-1-specific CD8 T-cell-mediated inhibition in infected cells expressing EV, RhT5, TCyp, and TCyp
plus CsA at 22 h postinfection. EVMM, EV-expressing cells in coculturewithHLA class I-mismatchedCD8T cells. The graph shows themean standard error
of the mean of three independent experiments performed in triplicate. The P values were calculated using a Wilcoxon signed-rank test. (G) Frequency of live
CD4-positive cells in EV-, RhT5-, TCyp-, and TCyp-CsA-expressing cells infected with HIV-1 in coculture with CD8 T cells. The graph shows the ratio of live
cells in the presence and absence of CD8 T cells. The bars represent the mean standard error of the mean of three independent experiments performed in
triplicate. The P values were calculated using two-way ANOVA corrected by the Bonferronimethod formultiple comparisons. Only significant values are shown
in the figures (***, P	 0.0001; **, P	 0.001; *, P	 0.01). Experiments shown in panels C to G were performed at an MOI of 0.2.
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by TCyp leaves more infected T cells to be inhibited by CD8 T
cells despite the absence of differences in total cell deaths between
RhT5- and TCyp-expressing cells. Nevertheless, our data demon-
strate that both RhT5 and TCyp restriction factors increase the
antigenicity of HIV-1-infected cells and improve HIV-1-specific
CD8 T-cell killing of infected cells.
TRIM5 expression in HIV-1-infected cells enhances activa-
tion of HIV-1-specific CD8 T cells.Next, we sought to examine
whether TRIM5 antiviral activity was required for direct activa-
tion of HIV-1-specific CD8 T-cell responses. To do this, we in-
hibited TRIM5 activity prior to coculture with HIV-1-specific
CD8 T cells and monitored changes in CD8 T-cell activation.
Although previous studies have identified HIV-1 mutants with
reduced sensitivity to RhT5 and TCyp, these mutants are never
fully resistant to TRIM5; in addition, their sensitivity is sequence
dependent and varies across cell types (27, 28). Therefore, for our
purposes, we decided to use an analogue of CsA, the drug SmBz-
CsA (29). We observed that SmBz-CsA acted as an inhibitor of
TRIM5 activity by recovering HIV-1 infectivity in cells expressing
both RhT5 (from 3% to 13.3%) and TCyp (from 12% to 43%)
(Fig. 2A). Moreover, treatment with SmBz-CsA did not affect the
functionality of CD8 T cells lacking the immunosuppressive ef-
fect of CsA (Fig. 2B). Based on these in vitro properties, we used
SmBz-CsA to estimate the specific effect of RhT5 and TCyp ex-
pression in HIV-1-infected cells on CD8 T-cell activation. To
this end, we used twoCD8T cell lines specific for the recognition
of two HIV-1 epitopes, one in Gag and one in Pol. We cocultured
CD8 T cells with cells expressing RhT5 or TCyp infected with
HIV-1 in the presence or absence of SmBz-CsA or CsA and eval-
uated changes in CD8 T-cell activation based on the expression
FIG 2 HIV-1-infected cells expressing TRIM5 variants enhance CD8 T-cell activation. (A) Frequency of GFP cells in EV-, RhT5-, and TCyp-expressing cells
in the presence or absence of 5 M SmBz-CsA or CsA. The SmBz-CsA molecule is shown above the graph. Data are shown as the mean standard error of the
mean from three independent experiments performed in triplicate. (B) Frequency of CD107a/MIP-1 expression in HIV-1-specific CD8 T cells cocultured in
response to EV, RhT5, and TCyp and in a B-cell line (BCl) loaded with cognate peptide. The data are from two independent experiments performed in duplicate.
(C) Representative zebra plot of the frequency of CD107a/MIP-1 expression in HIV-1 Gag- or Pol-specific CD8 T cells in coculture with infected cells
expressing RhT5 in the presence or absence of SmBz-CsA or CsA. (D) Activation levels were measured by the frequency of CD107a/MIP-1 in HIV-1
Gag-specific CD8 T cells cocultured with RhT5- or TCyp-expressing cells infected with HIV-1 in the presence or absence of AZT, SmBz-CsA, or CsA. (E)
Activation levels weremeasured by the frequency of CD107a/MIP-1 in Pol-specific CD8T cells cocultured with RhT5- or TCyp-expressing cells infected with
HIV-1 in the presence or absence of AZT, SmBz-CsA, or CsA. (F) Representative zebra plot showing CD107a/MIP-1 expression in HIV-1 Gag- or Pol-specific
CD8 T cells in response to peptide pulse control B cells loaded with cognate peptide. The P values were calculated using aMann-Whitney test. Only significant
values are represented (***, P	 0.0001; **, P	 0.001; *, P	 0.01). Experiments shown in panel A and in panels C to E were performed at an MOI of 0.2.
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of CD107a/MIP-1 (Fig. 2C). Consistently, we observed that
treatment with SmBz-CsA significantly reduced activation of
HIV-1 Gag-specific CD8 T cells in the cocultures (RhT5 versus
RhT5 plus SmBz-CsA, P
 0.002; TCyp versus TCyp plus SmBz-
CsA, P 
 0.018) (Fig. 2D), indicating a direct effect of TRIM5
expression in CD8 T-cell activation. Meanwhile, a trend was
observed forHIV-1 Pol-specificCD8T cells (Fig. 2E).Moreover,
treatment with AZT, resulting in 50% virus inhibition in all of the
cell lines used, did not affect CD8 T-cell activation levels. This
finding is consistent with the notion that CD8 activation in our
experiments results from antigen presentation of the incoming
viral particles (Fig. 2D and E). Discrepancies between the Gag-
and Pol-specific CD8 T-cell activation levels observed could not
be attributed to initial differences in functionality (Fig. 2F), thus
suggesting a TRIM5-specific effect.
We also tested IFN- release as an additional marker of CD8
T-cell activation in response to TRIM5 antiretroviral activity. We
used an ELISPOT assay to detect IFN- owing to the low sensitiv-
ity of intracellular cytokine staining under the previous experi-
mental conditions. As shown in Fig. 3A, we observed target-to-
effector dose-dependent IFN- production of Gag-specific CD8
T cells following coculture with RhT5- and TCyp-expressing cells
infected with HIV-1. In addition, we observed differences in
IFN- production between RhT5 and TCyp variants. Thus, RhT5
showed a higher potency than TCyp for activation of Gag-specific
CD8 T cells as measured using IFN- production (RhT5 versus
TCyp, P 
 0.0313) (Fig. 3A). In agreement with the previous
experiment, the differences observedwere specific toCD8T cells
recognizing Gag (Fig. 3B).
Our findings were further confirmed in H9 HLA-B*5701 EV-
or RhT5-expressing cells infected with HIV-1 and coculture with
additional HLA-class I-matched Gag-specific CD8 T cells. As
shown in Fig. 4A, we observed an increase in IFN- production of
Gag-specific CD8 T cells in cocultures of RhT5-expressing cells
compared to levels in EV-expressing cells. As expected, similar
findings were observed in ourU937 experimentalmodel (Fig. 4B).
Overall, these data support the contribution of RhT5 and TCyp to
increased HIV-1-specific CD8 T-cell antiviral activity in re-
sponse to infection. Moreover, we observed a species-specific ef-
fect of the TRIM5 variant and a CD8 T-cell-specific effect on the
HIV-1 protein being recognized.
TRIM5 antiretroviral activity recruits the viral capsid and
favors contacts with the cellular proteasome. The activation of
CD8 T cells relies on efficient antigen presentation through the
class I processing pathway (30), which ultimately presents prepro-
cessed viral epitopes on the surface of HLA class I molecules. The
association between the level of antigen and the magnitude of
specific CD8 T-cell responses (31) suggests a role for TRIM5
expression in delivering viral antigens forHLA class I presentation
that will translate into enhanced CD8 T-cell activation. To gain
further insights into the mechanism that promotes CD8 T-cell
activation in this system, we measured intracellular capsid levels
and quantified HIV-1 contacts with the proteasome as an indica-
tor of protein recruitment and degradation for HLA class I pre-
sentation.Wemeasured capsid levels by intracellular p24 staining
in the three different lines and found an accumulation of p24 in
RhT5- and TCyp-expressing cells infected with HIV-1 compared
with the level in EV-expressing control cells (EV versus RhT5, P	
0.0001; EV versus TCyp, P
 0.024) (Fig. 5A) and a reduction in
the ratio of GFP/p24 cells in RhT5- andTCyp-expressing cells (EV
versus RhT5, P	 0.0001; EV versus TCyp, P	 0.0001) (Fig. 5B).
These data suggest an association between retroviral restriction
and accumulation of the viral capsid.
We next quantified HIV-1 contacts with the cellular protea-
some in TRIM5-expressing cells as indirectmeasurements of pep-
tide availability for HLA class I loading. We incubated EV-,
RhT5-, and TCyp-expressing cells with GFP-Vpr-labeled HIV-1
and stained the cells for the 19S proteasome subunit in DAPI
mounting medium (Fig. 5C). We used confocal microscopy to
quantify HIV-1 contacts with cellular proteasomes (seeMovies S1
and S2 in the supplemental material) and observed an increase in
the number of HIV-1 contacts with the cellular proteasome in the
FIG 3 IFN- secretion in HIV-1 Gag- and Pol-specific CD8 T cells cocultured with HIV-1-infected cells expressing RhT5 and TCyp. RhT5- and TCyp-
expressing cells were infected with HIV-1GFP at an MOI of 0.5 and cocultured with HLA class I-matched HIV-1 Gag- or Pol-specific CD8
 T cells at various
effector/target (E/T) ratios (1:16, 1:8, 1:4, and 1:2) and incubated overnight. (A) IFN- spots per well in Gag-specific CD8 T cells. (B) IFN- spots per well in
Pol-specific CD8 T cells. Data are from two independent experiments performed in triplicate for panel A and from three independent experiments performed
in triplicate for panel B. The P values were calculated using aWilcoxon signed-rank test. Only significant values are shown in the figure (***, P	 0.0001; **, P	
0.001; *, P	 0.01).
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presence of RhT5 and TCyp variant expression (median RhT5
value, 56.25%; median TCyp value, 70.18%) compared with EV
(9.9%) (Fig. 5D). This observation is consistent with findings
from previous reports (32). In addition, the number of virus-
proteasome contacts per cell decreased after treatment of TCyp-
expressing cells with SmBz-CsA, suggesting a direct role of TRIM5
in virus-proteasome interactions (Fig. 6).
Taken, together these data demonstrate that TRIM5 variants
enhance CD8 T-cell activation and that such an increase is ac-
companied by capsid and proteasome recruitment in HIV-1-in-
FIG 4 IFN- secretion in HIV-1 Gag-specific CD8 T cells cocultured with H9 and U937 HIV-1-infected cells expressing EV and RhT5. H9 HLA-B*5701 and
U937 HLA-B*2705 EV- and RhT5-expressing cells were infected with HIV-1GFP at anMOI of 0.5 and cocultured with HLA class I-matched HIV-1 Gag-specific
CD8 T cells at an effector/target (E/T) ratio of 1:2 and incubated overnight. (A) IFN- spots per well in H9 HLA-B*5701 coculture with HLA-class I-matched
Gag-specific CD8 T cells. (B) IFN- spots per well in U937 HLA-B*2705 coculture with HLA class I-matched Gag-specific CD8 T cells.
FIG 5 TRIM5 retroviral restriction favors HIV-1 p24Gag recruitment and virus interactions with the cellular proteasome. (A) Intracellular p24Gag levels. (B.)
Ratio of GFP/p24-positive cells in EV-, RhT5-, and TCyp-expressing infected cells. Data are from six independent experiments performed in triplicate at anMOI
of 0.2. The P values were calculated using aMann-Whitney test. Only significant values are shown in the figure (***, P	 0.0001; **, P	 0.001; *, P	 0.01). (C)
Representative image of HIV-1 proteasome interactions in RhT5-expressing cells. The virus NL43-VprGFP is shown in green, the proteasome is shown in red,
and the cellular nucleus is shown in blue (DAPI). White arrows and boxed areas show HIV-1 contacts with the cellular proteasome. (D) Number of HIV-1
proteasome contacts in TRIM5-expressing cells. Data represent the number of contacts in five independent cells per condition.
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fected cells expressing TRIM5 and suggest a direct role for TRIM5
antiviral activity in virus-proteasome interactions.
DISCUSSION
Devising ways to activate both innate restriction factors and effec-
tive CD8 T-cell responses may provide the basis for novel ther-
apeutic strategies that can contribute to HIV-1 control during
acute infection (33). Here, we identified a novel role for two non-
human TRIM5 variants, RhT5 and TCyp, both of which are po-
tent restrictors of HIV-1 and inducers of HIV-1-specific CD8
T-cell responses. We demonstrated that RhT5 and TCyp proteins
are able to link innate retroviral restriction and CD8 T-cell an-
tiviral activity to improve cellular protection against retrovirus
infection.
We envisaged the following model (Fig. 7). The recognition of
incoming viral particles by RhT5 and TCyp variants enables at
least two antiviral activities: (i) capsid recognition-dependent
blockade of HIV-1 integration through the premature uncoating
of the viral particles and (ii) activation ofCD8T cells through the
recruitment of the viral particles to the cellular proteasome. These
interactions lead to increased peptide availability and efficient
peptide HLA class I loading and trafficking for antigen presenta-
tion by the incoming viral particles. Antigen presentation is more
abundant for capsid peptides and RhT5-expressing infected cells,
where these interactionswill lead to production of IFN- (Fig. 7A)
and CD107a/MIP-1 in HIV-1-specific CD8 T cells, than for
TCyp-expressing infected cells (Fig. 7B).
Although previous studies have evaluated the function of re-
striction factors in adaptive immunity, their role in antigenicity
varied depending on the restriction factor studied and cell type
analyzed. APOBEC3G expression is able to promote CD8 T-cell
responses, thus favoring peptide availability for proteasome deg-
radation through the generation of misfolded or truncated pro-
teins (19). The presence of SAMHD1 has a negative impact on
antigen presentation and CD8 T-cell activation in monocyte-
derived dendritic cells (18). Thus, only the restriction factors that
promoteCD8T-cell activation in the context of potent retroviral
restriction would favor sustained viral control in this way. To-
gether with APOBEC3G, TRIM5 has one of the strongest positive
selection signals in the human genome, thereby underscoring its
antiviral potency (22). However, human TRIM5 does not restrict
HIV-1 owing to evolutionary adaptation of the capsid (34),
whereas the primate TRIM5 orthologs RhT5 and TCyp do. Com-
pared with other restriction factors, TRIM5 has a particular ad-
vantage as it functions as a rapid viral sensor of incoming HIV-1
particles and therefore likely contributes to prevent seeding of the
viral reservoir.
Our data demonstrate a species-specific effect of TRIM5 vari-
ants as enhancers of the antigenicity of HIV-1-specific CD8 T-
cell responses in infected cells. Thus, RhT5 expression in HIV-1-
infected cells induced higher levels of CD8 T-cell activation than
that in TCyp-expressing cells. The differences observed may ac-
count for divergences in TRIM5 proteins between species. Al-
though the reasons for our findings are not fully understood, we
can hypothesize that differences in protein stability (35), capsid
recruitment, and affinity for proteasome interactions may ac-
count for the differential amounts of antigen being presented and
the differences in CD8 T-cell activation profiles.
Along with the species-specific effect on activation, our data
revealed an effect on CD8 T-cell viral protein specificity in re-
sponse to TRIM5 restriction. Thus, CD8 T cells targeting a viral
capsid epitope display higher levels of activation in response to
RhT5- and TCyp-expressing cells infected with HIV-1 than in
Pol-specific CD8 T cells. It is not clear why Pol epitopes, for
example, those derived from protease, integrase, or reverse trans-
criptase, are not more effectively presented in RhT5- and TCyp-
expressing cells. We hypothesize that this may due to the smaller
amounts of protein in the viral particle than those observed in
Gag. However, it may also be due to preferred degradation and
presentation of Gag-derived peptides because it is Gag-derived
capsid protein that is actually bound by TRIM5/TCyp. Intrinsic
epitope properties may also play a role (24, 35). Further studies
will help to clarify whether our findings extend to other HIV-1
CD8 T-cell responses with different epitope specificities and/or
avidity.
Previous studies suggested that HLA-B*27 can present pep-
tides independently of proteasomes and TAP (transporter associ-
ated with antigen processing) (36). However, epitope abundance
predicted by proteasomal digestion correlatedwith the hierarchies
of CD8 T-cell responses in HLA-B*27 HIV-1-infected individu-
als (37). These data suggest that the contribution of proteasome-
negative, TAP-negative antigen presentation is of minor impor-
tance in fully functional cells, where proteasome-dependent
FIG 6 HIV-1 TRIM5-mediated restriction contributes to viral particle recruitment to the proteasome. (A) Number of virus particles per cell. (B) Frequency of
cells with viruses with at least a viral contact with the proteasome. Data represent the number of virus/contacts in five independent cells per condition.
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pathways outcompete alternative antigen presentation pathways
(38).
The precise mechanistic details of this mechanism of CD8
T-cell-mediated activation of TRIM5 should be investigated in
further detail. However, we hypothesized that theymay be depen-
dent on the TRIM5 E3 ligase activity that promotes the generation
of polyubiquitinated chains of TRIM5 proteins, leading to their
subsequent recruitment to the cellular proteasome. The role of
polyubiquitination of TRIM proteins was recently described as a
mechanism to synergize innate signaling and virus degradation in
TRIM21, TRIM5, and TRIM25 (7, 10, 39).
We establish a new mechanism of action for nonhuman
TRIM5 proteins in HIV-1 specific CD8 T-cell activation.
Our study is limited to the use of immortalized cell lines, and
further studies are ongoing to evaluate the contribution of TRIM5
restriction to CD8 T-cell antigen presentation in primary CD4
lymphocytes. Although human TRIM5 is not thought to strongly
restrict HIV-1 infection in humans, we hypothesized that in cer-
tain cases, for example, under selective pressure to escape Gag-
directed CD8 T-cell responses (40), HIV-1 variants sensitive to
humanTRIM5may arise. In this case, we expect humanTRIM5 to
contribute to T-cell-mediated killing of infected cells, as described
above.
The function of TRIM5 proteins as restriction factors and pat-
tern recognition receptors (10), together with the function de-
scribed here as enhancers of HIV-1 CD8 T-cell recognition,
make them good candidates for novel therapeutic strategies
against HIV-1. Such therapies could target the generation of novel
gene therapy vectors, where promising results have already been
obtained (41, 42), or small molecules that mimic the function of
TRIM5 proteins. In this context, TRIM5-based gene therapy vec-
tors will have an additional protective immune function through
induction of antiviral CD8 T-cell responses.
Our findings offer new insights into the interplay between
HIV-1, TRIM5 retroviral restriction, and adaptive cellular immu-
nity that should be explored in detail to develop innovative strat-
egies that can be widely applied to control retroviruses.
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